Catecholamine Research in the 21st Century, 1st Edition

  • Published By:
  • ISBN-10: 0128000732
  • ISBN-13: 9780128000731
  • DDC: 617.378
  • Grade Level Range: College Freshman - College Senior
  • 328 Pages | eBook
  • Original Copyright 2013 | Published/Released June 2014
  • This publication's content originally published in print form: 2013

  • Price:  Sign in for price



Through the use of extended graphical abstracts and some traditional text-only abstracts this collection provides, a record of and roadmap to, the research presented at The Tenth International Catecholamine Symposium (XICS) held in September of 2012. Organized around ten general themes, each is introduced by a short overview identifying interesting research programs, results and potential areas of growth. The collection is a roadmap to key research and future opportunities for new catecholamine research programs and will be of interest to neuroscientists and clinical neurologists interested in understanding the current and future state of catecholamine research.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
Table of Contents.
1: Catecholamine Biosynthesis and Storage.
2: Genetic Manipulation of Catecholamine Signaling in the Mouse.
3: AADC Deficiency: Occurring in Humans; Modeled in Rodents; Treated in Patients.
4: Tyrosine Hydrolylase and Dopamine Beta-Hydroxylase: Role of Common Genetic Variation in Adrenergic Responses to Stress and in Hypertension.
5: Pharmacokinetic and Pharmacodynamic Properties of Etamicastat, a New DBH Inhibitor: Comparison to Nepicastat.
6: Estradiol-Mediated Regulation of Gene Expression of Catecholamine Biosynthetic Enzymes: The Role of Membrane-Initiated Signaling with Erα.
7: Structural Basis for Regulation of Tyrosine Hydroxlyase by the Catecholamines.
8: Unique Regulation of TH Gene Expression in Midbrain Dopamine Neurons.
9: Intracellular Stability of Tyrosine Hydroxylase: Phosphorylation and Proteasomal Digestion of the Enzyme.
10: The Peripheral Interaction of Tyrosine Hydroxylase and 14-3-3γ with Negatively Charged Phospholipidic Membranes.
11: Dynamic Regulation of Tyrosine Hydroxylase Gene Expression by Key Fate-Determining Transcription Factors during Dopaminergic Neuronal Development in Vivo and in Vitro.
12: Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease.
13: Non-dopaminergic Neurons Partly Expressing Dopaminergic Phenotype: Functional Significance and Regulation.
14: Developing Brain as an Endocrine Organ: Catecholamines Secretion and Endocrine Action.
15: Brainstem DOPAergic System.
16: Imaging Norepinephrine Transporters in Humans; Translational Research with PET.
17: Imaging the Vesicular Monoamine Transporter (VMAT2) in Neurodegenerative Diseases.
18: GTP Cyclohydrolase Regulation: Implications for Brain Development and Function.
19: Neonatal Diagnosis of Menkes Disease by a Pattern of Plasma Catechols.
20: Catecholamine Metabolites Affected by the Copper-Dependent Enzyme Dopamine-Beta-Hydroxylase Provide Sensitive Blood and Csf Biomarkers for Viral Gene Therapy in Menkes Disease.
21: Are the Enzymes of the Catecholamine Biosynthetic Pathway Locally Synthesized in the Axon?.
22: Effects of Missense Mutations in Tyrosine Hydroxylase (TH) Found in Patients with Neurological Disorders Attributed to TH Deficiency.
23: Tetrahydrobiopterin Deficiency Impairs Postnatal Increase of TH Protein via Insufficient Dopamine Biosynthesis.
24: Selective Ablation of Dopamine Beta-Hydroxylase Neurons (Subpopulation of TH Neurons) in the Brain: New Insights into Brain Catecholaminergic Circuitry and Catecholamine-Related Diseases.
25: Neural Circuit Mechanism for Learning Dependent on Dopamine Transmission: Roles of Striatal Direct and Indirect Pathways in Sensory Discrimination.
26: Regulation of Tyrosine Hydroxylase by Ser19-Phosphorylation-Dependent Binding to 14-3-3γ.
27: Modeling the Dynamics of Dopamine Biosynthesis and its Regulation by Tyrosine Hydroxylase.
28: Reassessment of Intrinsic Dopaminergic Innervation in the Human Enteric Nervous System – Clinical Implications.
29: Midbrain Dopamine Neurons are Divided into Different Functional Groups.
30: Cell-, Region- and Species-Specific Expression of VMAT2: Implications for Medical Imaging With High-Affinity Transporter Ligands.
31: Catecholamine Release and Re-uptake.
32: Detecting Catecholamines – A Journey from Beaker to the Behaving Brain.
33: Functional Disturbances in DA Homeostasis and Signaling Revealed Through the Study of Rare Dopamine Transporter Coding Variants.
34: Norepinephrine Transporter A457P Knockin Mice Display Tachycardia and Anxiety-Like Behavior.
35: In Vivo Mutations in the Trafficking Domain of the Drosophila Vesicular Monoamine Transporter Disrupt Specific Amine-Dependent Behaviors.
36: Fate of the Chromaffin Granule Membrane and its Protein Constituents after Fusion.
37: Catestatin (Human Chromogranin A352-372) Induces Lipolysis and Fatty Acid Oxidation through Regulation of Adrenergic and Leptin Signaling.
38: Introduction: From Mystery Matrix Proteins to Precise Molecular Actions in Human Disease.
39: A New Take on Uptake: Dopamine Transporters & the Cellular Mechanisms of Amphetamine Action.
40: A Retrospective on PET and the Amphetamine Paradigm: Validation and Paradoxes.
41: The Corelease of Glutamate by Dopamine Neurons.
42: Psychostimulant-Induced Alterations of Monoaminergic Transporters: Implications for Neurotoxicity and Neuroprotection.
43: Trace Amine Associated Receptor 1 is a Catecholamine Receptor that Differentially Controls DAT and NET Internalization.
44: VGF-Derived Peptide TLQP-21: Structure, Function, and Biomedical Implications.
45: Chromogranins the Key Proteins for the Storage and Regulation of Exocytosis in Chromaffin Cells.
46: Chromogranin A in the Storage and Exocytosis of Catecholamines.
47: The Involvement of Vesicular ATP in the Storage and Exocytosis of Catecholamines of Bovine Chromaffin Cells.
48: The Role of Ca2+ Release from the Endoplasmic Reticulum in the Catecholamine Hypersecretion of Adrenal Chromaffin Cells from Spontaneously Hypertensive Rats.
49: PACAP as a Primary Effector of the Acute Sympatho-Adrenal Stress Response.
50: Amphetamine Induced Dopamine Release in Macaque Monkeys: Striking Differences Between Prefrontal Cortex and Caudate Nucleus.
51: Attenuated Amphetamine-Induced Dopamine Release in Subjects at Ultra-High Risk for Substance Dependence.
52: The Membrane-Raft Protein Flotillin-1 is Essential in Dopamine Neurons for Amphetamine-Induced Behavior in Drosophila.
53: Plant Flavonoids Affecting Adrenal Medullary Catecholamine Biosynthesis and Release.
54: A Protein Complex for Dopamine Synthesis and Vesicular Storage: Target for Cellular Oxidative Damage.
55: Overexpression of Parkin in The Nigrostriatal System Might Protect Dopaminergic Terminals From Methamphetamine Neurotoxicity Via Regulation of Dopamine Transporter.
56: Increased Catecholamine Toxicity in Mice with Low Expression of VMAT2.
57: Metabolism.
58: Renalase: A New Player in Catecholamine Metabolism.
59: Abnormal Monoamine Oxidase A VT in the Prefrontal and Anterior Cingulate Cortex During Major Depressive Episodes and High Risk States for Major Depressive Episodes.
60: CNS Catecholamine Metabolism – Emerging Concepts.
61: Catestatin (Human Chromogranin A352-372) Induces Lipolysis and Fatty Acid Oxidation through Regulation of Adrenergic and Leptin Signaling.
62: Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models.
63: Understanding Catecholamine Metabolism as a Guide for Assessment of Sympathoadrenal Function and Dysfunction in Health and Disease.
64: Multiplex Immunoassay for Catecholamines.
65: Modifiers of Neurofibromatosis-Associated Tumors and the Potential Role for Catecholamines and Sex Differences.
66: Catecholamine Metabolism in Chromogranins Knock-Out Mice.
67: Translation Research in Autism and Cancer: Novel Roles of MAO.
68: COMT is a Major Contributor to Pain Perception: from Humans to Rats and Back to Humans.
69: Novel COMT Inhibitors in Parkinson Disease.
70: Effect of Opicapone, a New Catechol-O-Methyltransferase Inhibitor, in Levodopa Pharmakokinetics in the Cynomolgous Monkey.
71: Does Impaired Aldehyde Detoxification Play a Role in Parkinson's Disease?.
72: The Role of Aldehyde Detoxification in Parkinson's Disease.
73: Pharmacological Profile of Opicapone in Wistar rat.
74: Catecholamine Receptors and Catecholaminergic Signaling.
75: How Drugs Bind and Control their Targets: Characterizing GPCR Signaling through Long-Timescale Simulation.
76: Structural basis of Subtype Selectivity in Dopamine D3 and D2 Receptors.
77: Hormone-Mediated Activation of G Proteins by GPCRs: Insights from the Crystal Structure of a GPCR-G Protein Complex.
78: Towards Better Understanding of G(s) Coupling in Catecholamine Receptors.
79: Receptor Heteromerization: Understanding the Functional and Pathological Role of the Dopamine D4 Receptor.
80: Trace Amines and Their Receptors: New Opportunities for Modulation of Brain Dopaminergic Functions.
81: Cross-Talk between G Protein-Coupled Receptors: Challenges of Distinguishing Upstream from Downstream Mechanisms.
82: Growth Hormone Secretagogue Receptor (GHSR1a, aka Ghrelin Receptor) is an Allosteric Modulator of Dopamine Signaling in the Brain via Formation of GHSR1a:DRD2 and GHSR1a:DRD1 Heteromers.
83: Regulation of β2Adrenergic Receptor Trafficking and Signaling by Ubiquitination and Deubiquitination.
84: Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling.
85: Trafficking of the D2 Dopamine Receptor Promotes Drug-Induced Changes in Neuronal and Behavioral Plasticity.
86: D2 Receptors Control of Dopamine Levels.
87: Integrated Approaches to Understand the Actions of GPCRs: The b-Arrestin-Dependent D2R Mediated Signaling Through Akt/GSK3.
88: Hyperdopaminergic Modulation of Inhibitory Transmission is Dependent on GSK-3β Signaling-Mediated Trafficking of GABAA Receptors.
89: Simultaneous, Massively Parallel and Genome-Wide Interrogation of GPCR b-arrestin-ergic Signaling: Implications for GPCR Drug Discovery and Catecholamine Biology.
90: Backwards and Forwards with Molecular and Classical Pharmacology.
91: Targeting Beta-Arrestin Dependent Signaling in the Treatment of Parkinson's Disease.
92: D2 Functionally Selective Ligands: novel Therapeutics?.
93: Investigation of the D1-D2 heteromer: pharmacology, subunit composition, and mechanisms of signaling.
94: β-Adrenergic Receptors, Caveolae and Caveolins: Receptor Localization and Function.
95: Protein Kinase C β and the Dopamine Transporter Influence Surface D2-Like Dopamine Receptor Localization.
96: Role of Adrenaline on the Maturation of β2-Adrenoceptors.
97: Deciphering the Functionally Selective Properties of D2R Ligands.
98: Chronic loss of Noradrenergic Tone Produces β-Arrestin2-Mediated Cocaine Hypersensitivity and a GαI to Gαs switch in D2 Receptor Coupling in the Nucleus Accumbens.
99: Probing the Functional Selectivity of β-adrenergic Receptors Reveals New Signaling Modes and Potential Therapeutic Applications.
100: Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor.
101: Novel cAMP Sensor Links GPCR-Gs Signaling to ERK in Neuroscreen-1 Cells.
102: High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes.
103: Discovery and Characterization of TAAR1 Agonists, Modulators of Dopaminergic and Serotonergic Neurotransmission with Therapeutic Potential in Neuropsychiatric Disorders.
104: Neurology.
105: Modeling Parkinson's Disease in a Mouse Model Overexpressing Astrocytic Monoamine Oxidase B (MAO-B): Towards Exploring Novel Therapeutics.
106: 3,4-Dihydroxyphenylacetaldehyde is an Autotoxic and Protein-Reactive Intermediate of Dopamine Catabolism.
107: Dopamine Oxidation and Quinone Modification of Proteins: Mechanisms of Toxicity and Implications for Parkinson's Disease.
108: Insights into LRRK2-Mutation Related PD from PET Imaging Studies.
109: Norepinephrine Deficiency in Parkinson Disease.
110: Progressive Noradrenergic Degeneration in Mice with Reduced Expression of the Vesicular Monoamine Transporter (VMAT2).
111: LRRK2 and Risk of PD.
112: Synuclein-Mitochondrial Interactions in Substantia Nigra Dopamine Neurons.
113: Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson's Disease.
114: Induction of Chaperone-Mediated Autophagy as a Means to Attenuate Alpha-Synuclein-Mediated Neurotoxicity.
115: The Link between Neuronal Phenotype and Vulnerability in Parkinson's Disease.
116: Willie Sutton's Getaway Car and the Pathogenesis of Parkinson Disease.
117: Contributions of Dopamine in the Dorsal Striatum to Behaviors Corresponding to Cognitive Dysfunction in Parkinson's Disease.
118: Cardiac Sympathetic Denervation: A Biomarker of Lewy Body Diseases.
119: Cerebrospinal Fluid Biomarkers of Central Catecholamine Deficiency in Parkinson Disease and Other Synucleinopathies.
120: Comparison Between Myocardial Sympathetic and Striatal Dopaminergic Imaging in Lewy Body Diseases: “Union is strength!”.
121: A Role For Neuronal MHC-I Display in Parkinson's Disease?.
122: Modeling of Preclinical and Clinical Stages of Parkinsonism in MPTP-treated Mice with Focus on Tyrosine Hydroxylase in Survived Nigrostriatal Dopaminergic Neurons.
123: Role of Multiple Factors in Susceptibility of Neurons in Parkinson's Disease.
124: Modeling of Presymptomatic and Symptomatic Stages of Parkinsonism in MPTP-treated Mice: Extra-nigrostriatal Manifestations.
125: Basal and Graded 6-OHDA –induced Differences in Striatal Dopamine and its Metabolites in two Mouse Lines with A30P–Mutated Alpha-Synuclein.
126: Rasagiline Reduces Striatal Dopamine Release and Extracellular Oxidative Stress in a Rat Model of Early Parkinson's Disease.
127: Approach Towards Development of Multifunctional Drugs As an Effective Strategy for Treatment of Parkinson's Disease.
128: Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models.
129: Psychiatry and Psychology.
130: Rewarding Dopamine.
131: Modulating Local Circuit Dynamics versus Long-Range Inputs.
132: Midbrain Dopamine Neurons are Divided into Different Functional Groups.
133: Dopamine System Dysregulation by the Hippocampus and the Pathophysiology of Schizophrenia.
134: The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia: In Vivo Evidence from the Prodrome to the First Psychotic Episode.
135: Striatal Dopamine Release in Schizophrenia Comorbis with Substance Dependence.
136: Neuroimaging Studies of Central Catecholaminergic Function in Depression.
137: Central and Peripheral Norepinephrine Secretion in Major Depression is Activated, as Assessed by 24 hour CSF and Plasma Sampling.
138: Norepinephrine: A Broken Spoke on the Wheel of Depression.
139: PET Imaging of Serotonin Transmission in Monkeys: Effects of Maternal Separation and Long-Term Fluoxetine Treatment during Adolescence.
140: Opposing Regulation of Norepinephrine and Dopamine in Rat Limbic Brain Regions in Response to Aversive Stimuli.
141: The Locus Coeruleus, Stress, Opioids and Behavioral Flexibility.
142: Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis.
143: Evaluation of [11C]ORM-13070 as a PET tracer for α2C-adrenoceptors in the human brain.
144: Drug Abuse and Addiction.
145: Addiction: Story of an Unbalanced Brain.
146: Essential Catecholamine Influences on Dorsolateral Prefrontal Cortical Cognitive Function: Molecular Signaling Pathways.
147: Neural Mechanisms Underlying the Cognition-Enhancing Actions of Pyschostimulants: Relevance to ADHD.
148: Frontostriatal Systems and Differential Roles of Dopamine D1- and D2-Like Receptors in Impulsivity and Response Inhibition.
149: Catecholamine Strategies for Remediating Fronto-Executive Deficits in Stimulant Addiction and Related Disorders.
150: Ultrastructural and Optogenetic Evidence for Dual Neuronal Signaling by Dopamine Neurons of the Ventral Tegmental Area (VTA).
151: Seeking reward: Upstream modulation of VTA dopamine neurons by orexin/hypocretin inputs.
152: Striatal Dopamine, Self-control and Decision-Making: Identifying Therapeutic Targets for Addiction through Brain Imaging.
153: Imaging Neurochemical Transmission in Substance Abuse: Commonalities and Differences Across Addictions.
154: Dopamine Transmission in Cocaine Addiction: Linking the Animal and Human Studies.
155: Growth Associated Protein-43, Amphetamine and Dopamine Transporter Activity.
156: The Role of Ion Binding in Transporter Conformational Transition.
157: Evidence for the Contribution of D4 Receptors to Cocaine Self-Administration in Monkeys.
158: Drug Design for Addiction – Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor.
159: Cue-Induced Dopamine Release in Striatal and Extra-striatal Regions in Cocaine Dependent Users: A High Resolution PET [18F]Fallypride Study.
160: β-arrestin Regulation of Ghrelin Signaling in modulating Addictive Behavior.
161: Dopamine D3 and D4 Receptors as Therapeutic Targets for Nicotine Addiction.
162: Long-Term Cocaine Exposure Affects Dopamine D3 Receptor Function.
163: Catecholamines in the Periphery.
164: Recurrent Hypoglycemic Stress Differentially Regulates Catecholamine Release and Transmitter Gene Expression.
165: Sympathetic Mechanism of Hypertension.
166: Harnessing the Autonomic System for Therapeutic Intervention.
167: Norepinephrine Transporter Function and Human Cardiovascular Regulation.
168: Role of Common Genetic Variation in Control of Human Adrenergic Function and Blood Pressure: Focus on the Chromogranins.
169: What is the Optimal Biochemical Diagnostic Strategy for Pheochromocytoma?.
170: SDHx-Related Pheochromocytoms: New Advances in Genetics and Functional Imaging.
171: Novel Methods Peripheral Autonomic Assessment.
172: Identification and Functional Characterization of Genetic Variants of the Catecholamine Release-Inhibitory Peptide Catestatin in an Indian Population.
173: The Osmopressor Response in Human Physiology.
174: Adrenergic Derived Myocardium: Anatomic Substrate for Stress Induced Cardiomyopathies.
175: The Relationship of Norepinephrine to Stress Induced Hypertension.
176: Regulation of Adrenal Phenylethanolamine N-methyltransferase Gene Expression and Adrenaline Synthesis in a Fetal Programming Model of Hypertension.
177: Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland.
178: Effect of Daidzein on Mean Arterial Pressure and Vascular Dysfunction in CLP-Induced Septic Mice.
179: Adrenal-Specific G Protein-Coupled Receptor Kinase (GRK)-2 Deficiency Reduces Circulating Catecholamine Levels and Improves Cardiac Function after Myocardial Infarction.
180: Serotonin and Catecholamines In Regulation of Myocardium Functions in Children with Congenital Heart Diseases.
181: “Genetic and Acquired Determinants of Postural Tachycardia Syndrome”.
182: Neurotransmitter dopamine regulates tumor growth.
183: Extra Virgin Olive Oil Increases Uncoupling Protein 1 Content in Brown Adipose Tissue and Enhances Noradrenaline and Adrenaline Secretions in Rats.
184: Neurovisceral Integration and Regulation of Peripheral Indices of ANS Function.
185: Catecholamines in Integrative Function.
186: Neuropeptide Y Infusion to Rats Attenuates Development of PTSD-Like Symptoms to Traumatic Stress.
187: PTSD and the Locus Coeeurleus.
188: Systems Biology and the Stress Response: From Pythagoras and the Epicureans to Modern Medicine.
189: Reactive Oxygen Species and Neuropeptide Y Signaling in Altered Catecholamine Synthesis during Intermittent Hypoxia.
190: Stress, HIF1a, and Adrenergic Function.
191: Characterization of Cerebrospinal Fluid (CSF) and Plasma NPY Levels in Normal Volunteers over a 24-h Timeframe.
192: NPY: Low Cerebrospinal Fluid (CSF) Levels in Posttraumatic Stress Disorder in Comparison to Combat and Civilian, non-combat Control Subjects.
193: Developmental Neuroendocrinology of Posttraumatic Stress Disorder in Children and Adolescents after Motor Vehicle Accidents.
194: Repeated and Novel Stress-triggered Changes in Adipocyte Catecholamine System.